Work

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Year: 2017

Type: article

Study design: Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(17)30181-x

Authors: Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, Takashi Ura, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Taroh Satoh, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuichiro Doki, Yuko Kitagawa

Institutions: The University of Osaka, Keio University, National Cancer Center Hospital, Aichi Cancer Center Hospital, National Cancer Centre Japan, National Cancer Center Hospital East, Shizuoka Cancer Center, Chiba Cancer Center, Saitama Cancer Center, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, National Cancer Center Exploratory Oncology Research & Clinical Trial Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, Ono Pharmaceutical

OpenAlex ID: W2596604644

FWCI: 24.22

Cites: 36

Cited by: 391

Related to: 9